Capricor Therapeutics, Inc. (CAPR) · Aug 24, 2026 · Other events

Capricor Therapeutics delays Deramiocel decision while narrowing its DMD label

PDUFA extended — Nov. 22 target, three months later; major amendment accepted for review

The FDA pushed Deramiocel’s decision to November 22 after accepting new data, but the narrower indication reflects unresolved review risk.

The expected August 22 FDA decision is now delayed three months. The filing moves the PDUFA target date to November 22, 2026, after the FDA classified Capricor’s amendment as a major amendment and accepted it for review. 〔0〕 This is a timing negative versus the standing expectation of an imminent approval decision, but it is not a rejection or a new complete response letter.

The company is trying to reshape the approval question around upper-limb preservation. Capricor submitted 24-month open-label data and additional robustness analyses while asking the FDA to evaluate a refined indication focused on upper-limb function, the primary endpoint of HOPE-3. 〔1〕 That narrows the commercial and regulatory claim, suggesting the original broader framing was not the cleanest path through review.

The clinical package still has a usable approval argument, but the filing does not remove regulatory uncertainty. Management says HOPE-3 met its primary endpoint with a statistically significant upper-limb benefit. 〔2〕 However, the need for a major amendment after the July advisory process means the FDA is still reassessing how the evidence supports the label, rather than simply processing a routine final review.

Net read: the delay is offset by a potentially more defensible indication, leaving the event genuinely two-sided. The FDA’s willingness to accept the added evidence and cite significant unmet need keeps the application alive, while the three-month delay pushes out the catalyst and confirms that approval is not yet a near-certain administrative step. The key change is not new efficacy data alone; it is the shift from seeking a broader DMD claim toward an upper-limb-focused approval decision.

What to watch next

FDA decision on Deramiocel, November 22, 2026

Original filing on SEC EDGAR

Capricor Therapeutics delays Deramiocel decision while narrowing its DMD label | CAPR Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.